In this issue:
Newer antiandrogens may increase risk of cognitive toxicity
PEACE-1: radiotherapy plus intensive systemic therapy for low-volume mCRPC
177Lu-PSMA-617 delays deterioration in quality of life
PFS benefit to front-line talazoparaib plus enzalutamide for mCRPC
Early detection of prostate cancer:AUA/SUO Guideline
CD46-targeted 225Ac alpha particle radioimmunotherapy promising
PBAC July agenda
Dry July supports men with prostate cancer
Piflufolastat F18 may be approved in the EU
American Indian men are less likely to undergo prostate cancer screening
CLARIFY trial of Cu-64 SAR-bisPSMA PET tracer will commence this year
COVID-19 resources
Conferences & Workshops
Please login below to download this issue (PDF)